Effect of multivitamin supplements on weight gain during pregnancy among HIV-negative women in Tanzania

Freeman T. Changamire*, Ramadhani S. Mwiru†, Karen E. Peterson†‡, Gernard I. Msamanga§, Donna Spiegelman¶**, Paul Petraro†, Willy Urassa††, and Wafaie W. Fawzi†‡‡

*Department of Family Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA
†Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
‡Human Nutrition Program, Department of Environmental Health Sciences, University of Michigan, Ann Arbor, Michigan, USA
§Department of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
¶Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
**Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA
††Department Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
‡‡Department of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts, USA

Abstract

Multivitamin supplementation has been shown to reduce the risk of low birthweight. This effect could be mediated through gestational weight gain. However, the effect of multivitamin supplementation on weight gain during pregnancy has not been fully studied. The objective of this study was to examine the effects of multivitamins on pregnancy weight gain. We enrolled 8468 HIV-negative women from Dar es Salaam, Tanzania, in a randomised, placebo-controlled trial of multivitamins on birth outcomes. Women were randomly assigned to receive either a daily oral dose of multivitamin tablets or a placebo and were weighed every 4 weeks from enrolment until the last visit before delivery. Intent-to-treat analyses were carried out to examine the effects of multivitamins on pregnancy weight gain. Multivariate linear and binomial regression models with...
the log-link function were used to examine the association of weight gain during pregnancy to birthweight. The overall total weight gain was 253 g (SE: 69, $P$: 0.0003) more, while the overall 4 weekly weight gain was 59 g greater (SE: 18, $P$: 0.005) among women who received multivitamins compared to placebo. Women in the lowest quartile of gestational weight gain had babies with an average birthweight of 3030 g (SD: 524), while women in the highest quartile had babies weighing 3246 g (SD: 486), on average. Prenatal multivitamin supplements increased gestational weight gain, which was a significant predictor of birthweight.

**Keywords**

weight; pregnancy; multivitamins; birthweight; Africa

**Introduction**

Low birthweight is a major determinant of neonatal mortality rates, which are still very high globally, especially in South Asia and sub-Saharan Africa (Ashworth 1998; WHO 2006). Inadequate weight gain during pregnancy is a major risk factor for low birthweight (Kramer 1987; Stein *et al.* 1995; WHO 1997; Neufeld *et al.* 1999). Improving maternal nutritional status before or during pregnancy could help prevent low birthweight and neonatal deaths in developing countries.

Evidence on the relationship between macronutrients and prenatal weight gain is evolving. Supplementation trials during pregnancy in developing countries have shown that total energy intake increases the rate of prenatal weight gain (Qureshi *et al.* 1973; Lechtig *et al.* 1975; Tontisirin *et al.* 1986; Prentice *et al.* 1987) and that isocaloric protein supplementation decreases maternal weight gain (Kramer 2000). Overall, however, the impact of macronutrient food supplementation on gestational weight gain appears to depend on the prior energy deficit, the impact being greater for those with low pre-pregnancy weight for height or in those women where food intake has been restricted (Institute of Medicine 1990, 2009). The effect of individual micronutrients such as zinc, iron and folate on pregnancy outcomes including birthweight has been looked at before (Goldenberg *et al.* 1995; Rasmussen 2001; Fall *et al.* 2003). However, there are a few studies that have examined the effect of multiple micronutrients supplementation on pregnancy weight gain. In one study among HIV-positive women in Tanzania, we showed that multivitamin supplementation increases pregnancy weight gain (Villamor *et al.* 2002). Another study conducted in Chile showed that women given a daily fortified milk product had higher weight gain in pregnancy than women who were given unfortified powdered milk (Mardones-Santander *et al.* 1988). Among women in Mexico, multivitamin supplements did not increase weight gain during pregnancy after adjusting for baseline differences in body mass index (BMI; Ramakrishnan *et al.* 2005).

We previously reported that multivitamins increased birthweight in a randomised trial of HIV-negative women (Fawzi *et al.* 2007). In that study, the incidence of low birthweight was 7.8% among infants in the multivitamin group and 9.4% among those in the placebo group [relative risk (RR), 0.82; 95% confidence interval (CI): 0.70, 0.95]. The mean...
The birthweight difference between the two groups was 67 g ($P < 0.001$). In this paper, we examined the effect of multivitamin supplements in the same trial on pregnancy weight gain, and assessed the relationship of gestational weight gain to birthweight.

**Subjects and methods**

**Study design and population**

We analysed data from 8468 HIV-negative women who participated in a randomised, double-blind, placebo-controlled trial in Dar es Salaam, Tanzania. Women were randomised between August 2001 and July 2004. The objectives of the trial were to determine if daily multivitamin supplementation during the prenatal period would reduce the incidence of fetal loss, low birthweight (< 2500 g) and preterm birth (< 37 weeks). The details of the study population for this trial have been described elsewhere (Fawzi et al. 2007). Consonant with standard prenatal care in Tanzania, women in both treatment groups also received daily supplements of 0.25 mg of folic acid, 60 mg of ferrous sulphate and malaria prophylaxis in the form of sulfadoxine–pyrimethamine tablets.

The participants were screened and recruited from women who attended antenatal clinics in Dar es Salaam. The basic eligibility requirements were a negative test for HIV infection, gestational age between 12 and 27 weeks according to the date of the last menstrual period, 18 years of age or older and an intention to deliver and stay in Dar es Salaam for at least 1 year after delivery. HIV type 1 serologic status was ascertained from all the women who consented to participate in the trial by means of two sequential enzyme-linked immunosorbent assay tests (Urassa et al. 1999). All women provided written informed consent to participate. Women were randomly assigned to receive either a daily oral dose of multivitamin tablets containing 20 mg of vitamin B$_1$, 20 mg of vitamin B$_2$, 25 mg of vitamin B$_6$, 100 mg of niacin, 50 μg of vitamin B$_{12}$, 500 mg of vitamin C, 30 mg of vitamin E and 0.8 mg folic acid or a placebo from enrolment until delivery.

Trained research nurses administered a questionnaire to all the women at enrolment during the second trimester to collect baseline data on the woman’s age, partner’s age, maternal education, marital status, parity, socioeconomic status and other behavioural and reproductive factors. In addition, nurses obtained a complete medical and obstetric history at baseline and performed clinical examinations at baseline and monthly.

Height was measured at baseline using a stadiometer to the nearest 0.1 cm with the subjects without head covers and shoes. Weight was measured to the nearest 100 g using balance scales with the women wearing light clothing without shoes.

Women were encouraged to deliver at Muhimbili Hospital, where research midwives attended to the delivery and weighed the infants to the nearest 10 g on a standard beam balance immediately after birth.

**Data analyses**

Analyses were limited to women who had a singleton pregnancy, a known date of pregnancy outcome and at least two weight measurements from enrolment through the end of gestation.
Data from women with fetal deaths were not excluded from the analyses. Compared with 779 women whose data were not included in this analysis, women who were included were significantly older, taller, had greater mid upper arm circumference (MUAC), lower gestational age at entry and lower haemoglobin. The distribution of the baseline characteristics was compared across the treatment groups by using the Wilcoxon rank sum and the Kruskal-Wallis test for continuous variables and \( \chi^2 \) tests for proportions. Intent-to-treat analyses were carried out to examine treatment effects on weight gain.

**Effect of supplements on gestational weight gain**—Changes in weight gain during pregnancy were examined in two ways: (1) as the total weight change over the period of follow-up [presented as means and standard deviations (SDs)]; (2) as 4-week changes in weight from one visit to the next controlling for the actual length of the inter-visit interval.

The weight difference between two consecutive visits (\( \Delta WEIGHT_{ij} \)) was modelled as a continuous response variable with the treatment assignment as the explanatory variable across the repeated measures in each individual using a generalised estimating equation approach (Diggle et al. 2002), according to the following model, \( \Delta WEIGHT_{ij} = \beta_0 + \beta_2 EXP_i + b_i + e_{ij} \)

Where \( E (b_i) = E (e_{ij}) = 0, \) \( \text{Var} (b_i) = \sigma_B^2 \) and \( \text{Var} (e_{ij}) = \sigma_w^2, \) \( WEIGHT_{ij} \) is the weight measurements during follow-up (\( j \)) for subject (\( i \)), \( EXP_i \) is the treatment assignment for subject (\( i \)), \( b_i \) is the between-person random error, \( e_{ij} \) is the within-individual random error, \( \sigma_B^2 \) is the between-person variance and \( \sigma_w^2 \) is the within-person variance. Robust estimators of the variance were used to construct CI and \( P \)-values in the analysis, and the working correlation structure allowed for negative correlations between successive pairs of measurements as would be expected for a dependent variable of this form.

Models for the effect of multivitamin supplementation on total weight gain controlled for gestational age at randomisation and time from the first weight measurement to the last weight measurement. Trimester specific analyses were done using data in each trimester. Only women having at least two weight measurements in each trimester were included. For the weight difference analysis, this means that intervals beginning in the second trimester and ending in the third trimester were excluded. The analysis of weight gain as a mediator between multivitamin supplementation and birthweight used the method of Lin, Fleming and DeGruttola (Lin et al. 1997). We also assessed whether the effect of supplements was modified by baseline characteristics, including BMI at entry to this study, haemoglobin (<11, \( \geq 11 \) g dL\(^{-1} \)), cluster of differentiation 4 (CD4) count as a marker of immune status with the median as the cut-off (<775, \( \geq 775 \) cells mm\(^{-3} \)) and malaria infection (malaria at baseline vs. no malaria), prematurity (defined as birth before 37 weeks of gestation.), the calendar months of the first and last measurements and the number of weight measurements. Modification of the effect of multivitamin supplementation on the total weight change was examined by adding the interaction terms of multivitamin supplementation with the potential modifier to a model with the main effects and testing by the robust score test.

**Birth outcomes in relation to rate of weight gain**—The association between total weight gain and birthweight was analysed using regression models controlling for
gestational age at first weight measurement, time from first to last weight measurement, and
time from last weight measurement to delivery, as well as the multivitamin group. The
possibly non-linear relationship between weight gain and birthweight was examined non-
parametrically with restricted cubic splines (Durrleman & Simon 1989) in a model adjusted
as described above.

To examine the relationship between gestational weight gain and birthweight outcome,
linear regression was used with birthweight as a continuous variable and total weight gain
categorised in quartiles. We adjusted for multivitamins regimen, BMI at randomisation,
height, marital status, parity, number of weight measurements, gestational age at delivery
and fetal sex.

We assessed whether the association between pregnancy weight gain and the risk of low
birthweight was modified by baseline BMI at entry to this study. The statistical significance
of this interaction was tested using the likelihood ratio test. Tests for non-linearity used the
robust score test for the continuous birthweight outcome and the likelihood ratio test for the
dichotomised outcome, comparing the model with only the linear term to the model with
both the linear and the cubic spline terms. Analyses were carried out with Statistical

Continuous variables are presented as mean (SD). Estimates based on models are presented
as estimate (95% CI). Categorical variables are summarised as per cents. Effects on binary
outcomes are summarised as RRs with 95% CI. All P-values are two-sided. A P-value ≤
0.05 is considered significant. No adjustments were made for multiple comparisons.

Results

A total of 8468 HIV-negative women were randomised, but only 7689 women with
singleton pregnancies and at least two weight measurements during pregnancy were
included in the analysis. Of these, 7378 women had live births, and the 7354 with known
birthweights were included in the birthweight analyses. The characteristics of our study
population are shown in Table 1. The distribution of baseline covariates, including the socio-
demographic characteristics, did not differ significantly across treatment regimens. The
mean gestational age at randomisation was 21 weeks (SD: 3.5) and the last visit before
delivery occurred at 36 weeks (SD: 3.9) on average. The average time from last weight
measurement to delivery was 3 weeks (SD: 2.7), and this did not differ across the treatment
regimens. There were 4.6 weight measurements per woman, independent of treatment
assignment and 95% of the women had three or more measurements. The women with ≥2
weight measurements were comparable between the multivitamins and the placebo groups
with respect to baseline characteristics.

The effects of multivitamins on weight gain are shown in Table 2. Multivitamin
supplementation increased the overall total weight gain by 253 g (95% CI: 177–388). The
total weight gain from randomisation to the last visit during pregnancy was 5501 g (95% CI,
5397–5605) in the multivitamin group, compared to 5248 g (95% CI: 5150–5346) in the
placebo group. The overall 4-weekly weight gain in the multivitamins group, 1379 g (95%
CI: 1349–1408), was significantly higher than that in the placebo group, 1319 (95% CI: 1291–1348). There was no difference in total weight gain or 4-weekly weight gains between placebo and multivitamin groups in the second trimester; however, there was a significant difference between the placebo and the supplementation groups in both the total weight gain, 125 g ($P = 0.001$) and the 4-weekly weight gains 70 g ($P = 0.0008$) in the third trimester. We found no significant interactions between multivitamins and baseline BMI ($P > 0.10$) Table 3.

There were 7378 women with live births. Of these, 7354 had infants with known birth weights. The relationship between total gestational weight gain and birth weight was linear as shown in Fig. 1 ($P = 0.001$). In the multivariate analysis, women in the lowest quartile of gestational weight gain had babies with an average birth weight of 3030 g (SD: 524), while women in the highest quartile gain had babies weighing an average of 3246 g (SD: 486). Baseline BMI did not modify the relationship between gestational weight gain and birth weight. Weight gain mediates 6.4% (95% CI: 2.2, 10.7%) of the effect of multivitamin supplementation on birth weight.

**Discussion**

We described the pattern of weight gain during pregnancy among HIV-negative women in Tanzania and examined the relationship between the rates of weight gain in pregnancy with birth weight. Multivitamin supplementation resulted in increases in both overall total weight gain (253 g; 95% CI: 177–388) and the 4-weekly weight gain (59 g; 95% CI: 18–100) in pregnancy. There was a significant difference between the placebo and the supplementation groups in both the total weight gain and the 4-weekly weight gain in the third trimester but not in the second trimester. Taken together, these findings may suggest that the effect of multivitamin supplements on gestational weight gain may be more pronounced during the third trimester than the second trimester. If confirmed in other studies, this may be reassuring as many women in Tanzania and other developing countries do not present to antenatal care, and hence be afforded the benefit of micronutrient supplementation, until later in the second trimester.

Multivitamins could improve the rate of weight gain in pregnancy through various mechanisms including improving the immune status that reduces the risk of infections (Bendich 2001). Furthermore, by restoring normal metabolism, multivitamins may restore the feeling of well-being, which may result in improved appetite (Committee on Nutrition 1958; Major et al. 2008). Furthermore, multivitamins particularly thiamine and B vitamins have a role in protein and energy metabolism, which could affect fetal growth by improving the fetus’ handling of macronutrients (Ashworth & Antipatis 2001), and result in higher maternal weight gain during pregnancy. Another mechanism, through which multivitamins could improve fetal growth, is via the antioxidant nature of vitamins such as C and E. There are studies that have shown that maternal oxidative stress plays an important role in the pathophysiology of low birth weight (Scholl & Stein 2001). Micronutrients might also improve birth outcomes by improving placental development and function (Ashworth & Antipatis 2001).
Our findings are in accord with other studies that have examined the effect of multivitamin supplementation on the rate of weight gain during pregnancy. A study that was conducted in a similar population in Tanzania in HIV-positive women showed that multivitamin supplementation resulted in an increase in maternal weight gain during the third trimester (304 g; 95% CI: 17,590) and a significant 30% reduction in the risk of weight loss. A study in Greece suggested that increases in serum vitamin C could lead to a higher total weight gain (Kafatos et al. 1989). In a supplementation trial in Chile which randomised women received a milk-based product fortified with thiamine, pyridoxine, niacin, vitamins A, C and E or a non-fortified milk product, total weight gain was significantly greater in the intervention group (Mardones-Santander et al. 1988). Among women in Mexico, however, multivitamin supplements did not increase weight gain during pregnancy after adjusting for baseline differences in BMI (Ramakrishnan et al. 2005).

We showed that an increase in rate of weight gain during pregnancy increases birth weight; however, the effect of the supplements on gestational weight gain explained only about 6% of the effect on birth weight.

There are studies that have shown that low rate of weight gain in pregnancy is associated with low birth weight (Abrams & Selvin 1995; Hickey et al. 1996; Berenson et al. 1997). Some studies, however, have shown that large gains in pregnancy weight are not always beneficial in terms of improving birth weight outcomes (Hickey et al. 1997; Nielsen et al. 2006). Most of these studies documented excessive weight gain to have adverse effects such as macrosomia with a higher risk for birth injury (Johnson et al. 1992), increased risk of operative delivery (Young & Woodmansee 2002) and increased risk for maternal morbidity particularly postpartum weight retention (Parker & Abrams 1993). In our study, the relationship between gestational weight gain and birth weight within the range of total weight gain of most of the women in our study (0–15 kg) was linear. The association of gestational weight gain and birth weight was not modified by baseline BMI.

A strength of our study is that its large size gave ample statistical power to examine the research questions of interest. One limitation, however, was that women were largely enrolled in the middle of the second trimester, which limited our ability to examine at the effect of multivitamins in pregnancy from conception through the first trimester and the ability to study weight changes in the first trimester and early second trimester.

In conclusion, multivitamin supplementation during pregnancy increased gestational weight gain among HIV-negative women in Tanzania. Birthweight increased with increased gestational weight gain. Further research is required to find the optimal weight gain in mothers in developing countries, and the effects of intervening earlier in pregnancy on gestational weight and on the risks of adverse pregnancy outcomes.

Acknowledgments

We thank the women who participated in this project; the study coordinator, Illuminata Balonzi; the study physician, Heavington Mshiu; and the research assistants, laboratory technicians, nurses, midwives and administrative staff who made the study possible. We also acknowledge the valuable input from Ellen Hertzmark.

Source of funding
This work has been supported by the National Institutes of Child Health and Human Development (NICHD R01 37701). FTC was supported by the Irene M. and Fredrick J. Stare Nutrition Education Fund.

References


Matern Child Nutr. Author manuscript; available in PMC 2015 July 01.


Key messages

- The effect of multivitamin supplementation on weight gain during pregnancy has not been fully studied.
- Multivitamin supplementation during pregnancy appeared to improve gestational weight gain and gestational weight gain is a predictor of birthweight.
- The effect of multivitamins on birthweight might be mediated through increase in gestational weight gain.
- Further research is required to find the optimal weight gain in mothers in developing countries, and the effects of intervening earlier in pregnancy on gestational weight and on the risks of adverse pregnancy outcomes.
Fig. I.
Birth weight in relation to total gestational weight gain.
Table 1

Maternal characteristics at baseline according to treatment assignment*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Placebo Mean (SD)</th>
<th>Multivitamin Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 3935)</td>
<td>(n = 3933)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>25.1 (5.1)</td>
<td>25.2 (5.1)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>155.3 (7.5)</td>
<td>155.4 (8.0)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>59.4 (10.6)</td>
<td>59.6 (10.5)</td>
</tr>
<tr>
<td>BMI (kg m(^{-2}))</td>
<td>24.6 (4.0)</td>
<td>24.6 (3.8)</td>
</tr>
<tr>
<td>MUAC (cm)</td>
<td>26.5 (4.3)</td>
<td>26.6 (4.0)</td>
</tr>
<tr>
<td>Education (years)</td>
<td>7.1 (2.8)</td>
<td>7.1 (2.9)</td>
</tr>
<tr>
<td>Parity</td>
<td>1.0 (1.3)</td>
<td>1.0 (1.3)</td>
</tr>
<tr>
<td>Wealth score†</td>
<td>1.6 (1.0)</td>
<td>1.6 (1.0)</td>
</tr>
<tr>
<td>Gestational age at recruitment (weeks)</td>
<td>21.2 (3.5)</td>
<td>21.3 (3.5)</td>
</tr>
<tr>
<td>Gestational age at last weight measurement (weeks)</td>
<td>36.3 (3.9)</td>
<td>36.4 (3.9)</td>
</tr>
<tr>
<td>CD4 count (cells mm(^{-3}))</td>
<td>804 (262)</td>
<td>807 (251)</td>
</tr>
<tr>
<td>Haemoglobin (g/100 mL)</td>
<td>10.3 (1.6)</td>
<td>10.2 (1.5)</td>
</tr>
<tr>
<td>Total energy intake (kcal)</td>
<td>2130 (866)</td>
<td>2129 (865)</td>
</tr>
<tr>
<td>Protein intake (g)</td>
<td>55 (34)</td>
<td>55 (33)</td>
</tr>
<tr>
<td>Carbohydrate intake (g)</td>
<td>351 (139)</td>
<td>351 (138)</td>
</tr>
<tr>
<td>Fat intake (g)</td>
<td>68 (42)</td>
<td>68 (43)</td>
</tr>
<tr>
<td>Time from randomisation to first diet measurement (weeks)</td>
<td>7.6 (1.7)</td>
<td>7.6 (1.7)</td>
</tr>
<tr>
<td>Time from last weight measurement to delivery (weeks)</td>
<td>3.0 (2.7)</td>
<td>3.1 (2.9)</td>
</tr>
</tbody>
</table>

CD4, cluster of differentiation 4; MUAC, mid upper arm circumference; SD, standard deviation.

* None of the baseline characteristics were significantly different between the treatment groups.

† Filmer-Pritchett wealth score.
Table 2

Estimated total weight gain and weight gain by trimester for women in placebo and multivitamin arms*

<table>
<thead>
<tr>
<th>Outcome</th>
<th>N</th>
<th>Placebo Mean (SD)</th>
<th>N</th>
<th>Multivitamins Mean (SD)</th>
<th>Difference* (SE)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated total weight gain (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall: from baseline to last visit†</td>
<td>3749</td>
<td>5248 (5150, 5346)</td>
<td>3835</td>
<td>5501 (5397, 5605)</td>
<td>253 (177, 388)</td>
<td>0.0003</td>
</tr>
<tr>
<td>Second trimester</td>
<td>2758</td>
<td>1316 (1214, 1418)</td>
<td>2753</td>
<td>1400 (1304, 1496)</td>
<td>84 (−23, 191)</td>
<td>0.12</td>
</tr>
<tr>
<td>Third trimester</td>
<td>3407</td>
<td>2618 (2549, 2686)</td>
<td>3408</td>
<td>2743 (2671, 2814)</td>
<td>125 (30, 220)</td>
<td>0.001</td>
</tr>
<tr>
<td>Estimated 4 week weight gain (g)‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>3749</td>
<td>1319 (1291, 1348)</td>
<td>3735</td>
<td>1379 (1349, 1408)</td>
<td>59 (18, 100)</td>
<td>0.005</td>
</tr>
<tr>
<td>Second trimester</td>
<td>2758</td>
<td>1395 (1347, 1443)</td>
<td>2753</td>
<td>1447 (1399, 1496)</td>
<td>52 (−19, 123)</td>
<td>0.15</td>
</tr>
<tr>
<td>Third trimester</td>
<td>3407</td>
<td>1316 (1280, 1351)</td>
<td>3408</td>
<td>1385 (1348, 1422)</td>
<td>70 (18, 121)</td>
<td>0.008</td>
</tr>
</tbody>
</table>

SD, standard deviation.

* Based on generalized estimating equations (GEE) models controlling for gestational age at first weight and the time from to last weight measurement (estimated at the median values of the covariates for each time group).

† From 21 to 36 weeks of gestation, on average.

‡ Based on GEE models controlling for time between measurements.
Table 3
Effects of multivitamin supplementation on gestational weight gain stratified by body mass index (BMI) at baseline*

<table>
<thead>
<tr>
<th>BMI category (kg m(^{-2}))</th>
<th>N</th>
<th>Effect estimate† (kg)</th>
<th>P-value</th>
<th>P for interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;22</td>
<td>1890</td>
<td>0.17</td>
<td>0.17</td>
<td>0.41</td>
</tr>
<tr>
<td>22–&lt;25</td>
<td>2391</td>
<td>0.22</td>
<td>0.07</td>
<td></td>
</tr>
<tr>
<td>25–29</td>
<td>2005</td>
<td>0.39</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>≥30</td>
<td>656</td>
<td>0.23</td>
<td>0.39</td>
<td></td>
</tr>
</tbody>
</table>

* Baseline was 21 weeks of gestational age, on average.

† Weight gained by those in the multivitamin group – weight gained by those in the placebo group based on generalized estimating equations (GEE) models.